Hyperprolactinemia in children: Clinical features and long-term results

Journal of Pediatric Endocrinology and Metabolism

Volumn 25, Issue 11-12, 2012, Pages 1123-1128

  Catli, Gonul ^a   Abaci, Ayhan ^a   Altincik, Ayca ^a   Demir, Korcan ^a   Can, Sule ^b   Buyukgebiz, Atilla ^c   Bober, Ece ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b Tepecik Research and Training Hospital   (Turkey)

^c ISTANBUL BILIM UNIVERSITY   (Turkey)

Author keywords

Bromocriptine; Cabergoline; Childhood; Hyperprolactinemia; Prolactinoma

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; HYPOPHYSIS HORMONE;

ADENOMA; ADOLESCENT; CANCER INVASION; CLINICAL ARTICLE; CLINICAL FEATURE; DRUG MEGADOSE; FEMALE; FOLLOW UP; GALACTORRHEA; HEADACHE; HORMONE DEFICIENCY; HUMAN; HYPERPROLACTINEMIA; MEDICAL HISTORY; MENSTRUATION DISORDER; MICROADENOMA; OBESITY; REVIEW; TRANSSPHENOIDAL SURGERY; VISUAL FIELD DEFECT;

ADOLESCENT; BROMOCRIPTINE; CHILD; COMBINED MODALITY THERAPY; ERGOLINES; FEMALE; HORMONE ANTAGONISTS; HUMANS; HYPERPROLACTINEMIA; PITUITARY NEOPLASMS; PROLACTINOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84872967314     PISSN: 0334018X     EISSN: 21910251     Source Type: Journal    
DOI: 10.1515/jpem-2012-0130     Document Type: Review

References (27)

1. Mindermann T, Wilson CB. Pediatric pituitary adenomas. Neurosurgery 1995;36:259 - 69.
2. Groote Veldman R, van den Berg G, Pincus SM, Frolich M, Veldhuis JD, et al. Increased episodic release and disorderliness of prolactin secretion in both micro- and macroprolactinomas. Eur J Endocrinol 1999;140:192 - 200.
3. Hu ZZ, Zhuang L, Dufau ML. Prolactin receptor gene diversity: structure and regulation. Trends Endocrinol Metab 1998;9:94 - 102.
4. Yu-Lee LY. Molecular actions of prolactin in the immune system. Proc Soc Exp Biol Med 1997;215:35 - 52.
5. Doknic M, Pekic S, Zarkovic M, Medic-Stojanoska M, Dieguez C, et al. Dopaminergic tone and obesity: an insight from prolactinomas treated with bromocriptine. Eur J Endocrinol 2002;147:77 - 84.
6. Tetlow LJ, Clayton PE. Tests and normal values in pediatric. In: Brook C, Clayton P, Brown R, editors. Brook ' s clinical pediatric endocrinology, 5th ed. Singapore: Blackwell Publishing, 2005:531 - 2.
7. Eren E, Yapici Ş, Çakir ED, Ceylan LA, Saǧlam H, et al. Clinical course of hyperprolactinemia in children and adolescents: a review of 21 cases. J Clin Res Pediatr Endocrinol 2011;3: 65 - 9.
8. Buyukbayrak EE, Karageyim Karsidag AY, Kars B, Balcik O, Pirimoglu M, et al. Effectiveness of short-term maintenance treatment with cabergoline in microadenoma-related and idiopathic hyperprolactinemia. Arch Gynecol Obstet 2010;282:561 - 6.
9. Coiro V, Volpi R, Cataldo S, Saccani-Jotti G, Magotti MG, et al. Increased arginine-vasopressin response to hypertonic stimulation and upright posture in idiopathic hyperprolactinemia. Regul Pept 2011;167:167 - 9.
10. Gold EB. Epidemiology of pituitary adenomas. Epidemiol Rev 1981;3:163 - 83.
11. Saranac L, Zivanovic S, Radovanovic Z, Kostic G, Markovic I, et al. Hyperprolactinemia: different clinical expression in chilhood. Horm Res Paediatr 2010;73:187 - 92.
12. Acharya SV, Gopal RA, Bandgar TR, Joshi SR, Menon PS, et al. Clinical profile and long-term follow-up of children and adolescents with prolactinomas. Pituitary 2009;12:186 - 9.
13. Fideleff HL, Boquete HR, Sequera A, Suá rez M, Sobrado P, et al. Peripubertal prolactinomas: clinical presentation and long-term outcome with different therapeutic approaches. J Pediatr Endocrinol Metab 2000;13:261- 7.
14. Colao A, Loche S, Cappa M, Di Sarno A, Landi ML, et al. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up. J Clin Endocrinol Metab 1998;83:2777 - 80.
15. Scacchi M, Pincelli AI, Cavagnini F. Growth hormone in obesity. Int J Obes Relat Metab Disord 1999;23:260 - 71.
16. Delgrange E, Donckier J, Maiter D. Hyperprolactinaemia as a reversible cause of weight gain in male patients ? Clin Endocrinol (Oxf) 1999;50:271.
17. Vasilev V, Daly AF, Vroonen L, Zacharieva S, Beckers A. Resistant prolactinomas. J Endocrinol Invest 2011;34:312 - 6.
18. Colao A, Loche S. Prolactinomas in children and adolescents. Endocr Dev 2010;17:146- 59.
19. Olafsdottir A, Schlechte J. Management of resistant prolactinomas. Nat Clin Pract Endocrinol Metab 2006;2:552 - 61.
20. Molitch ME, Thorner MO, Wilson C. Management of prolactinomas. J Clin Endocrinol Metab 1997;82:996 - 1000.
21. Tyson D, Reggiardo D, Sklar C, David R. Prolactin secreting macroadenomas in adolescents. Response to bromocriptine therapy. Am J Dis Child 1993;147:1057 - 61.
22. Webster J, Piscitelli G, Polli A, Ferrari CI, Ismail I, et al. A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. N Engl J Med 1994;331:904 - 9.
23. Biller BM, Molitch ME, Vance ML, Cannistraro KB, Davis KR, et al. Treatment of prolactin secreting macroadenoma with once-a-week dopamine agonist cabergoline. J Clin Endocrinol Metab 1996;81:2338 - 43.
24. Roth BL. Drugs and valvular heart disease. N Engl J Med 2007;356:6 - 9.
25. Valassi E, Klibanski A, Biller BM. Potential cardiac valve effects of dopamine agonists in hyperprolactinemia. J Clin Endocrinol Metab 2010;95:1025 - 33.
26. Fahie-Wilson MN, McKenna TJ, Ahlquist JA, Smith TP. Macroprolactin and the Pituitary Society guidelines for the diagnosis and management of prolactinomas. Clin Endocrinol (Oxf) 2007;67:638 - 9.
27. Fideleff HL, Boquete HR, Suarez MG, Azaretzky M. Prolactinoma in children and adolescents. Horm Res 2009;72: 197 - 205.